Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 West Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2022 Jul 29;13(8):1217-1218. doi: 10.1021/acsmedchemlett.2c00323. eCollection 2022 Aug 11.
Abstract
摘要
相似文献
1
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
ACS Med Chem Lett. 2022 Jul 29;13(8):1217-1218. doi: 10.1021/acsmedchemlett.2c00323. eCollection 2022 Aug 11.
2
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
ACS Med Chem Lett. 2023 Oct 19;14(11):1491-1492. doi: 10.1021/acsmedchemlett.3c00441. eCollection 2023 Nov 9.
3
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
ACS Med Chem Lett. 2022 May 13;13(6):883-884. doi: 10.1021/acsmedchemlett.2c00193. eCollection 2022 Jun 9.
4
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
ACS Med Chem Lett. 2022 Mar 4;13(4):528-529. doi: 10.1021/acsmedchemlett.2c00085. eCollection 2022 Apr 14.
5
Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases.
ACS Med Chem Lett. 2023 Jan 17;14(2):129-130. doi: 10.1021/acsmedchemlett.2c00526. eCollection 2023 Feb 9.
6
Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.
Expert Opin Investig Drugs. 2020 Mar;29(3):237-244. doi: 10.1080/13543784.2020.1723078. Epub 2020 Jan 31.
7
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.
J Med Chem. 2018 Apr 12;61(7):2823-2836. doi: 10.1021/acs.jmedchem.7b01625. Epub 2018 Mar 15.
8
Plasma kallikrein and diabetic macular edema.
Curr Diab Rep. 2010 Aug;10(4):270-5. doi: 10.1007/s11892-010-0127-1.
9
The Role of Plasma Kallikrein-Kinin Pathway in the Development of Diabetic Retinopathy: Pathophysiology and Therapeutic Approaches.
Semin Ophthalmol. 2016;31(1-2):19-24. doi: 10.3109/08820538.2015.1114829.
10
Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade.
J Allergy Clin Immunol Pract. 2022 Mar;10(3):716-722. doi: 10.1016/j.jaip.2021.11.011. Epub 2021 Nov 25.
引用本文的文献
1
Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration.
Cell Biochem Biophys. 2024 Jun;82(2):1159-1177. doi: 10.1007/s12013-024-01266-0. Epub 2024 Jun 13.
本文引用的文献
1
It is time for a moonshot to find "Cures" for diabetic retinal disease.
Prog Retin Eye Res. 2022 Sep;90:101051. doi: 10.1016/j.preteyeres.2022.101051. Epub 2022 Feb 11.
2
Hereditary Angioedema.
Emerg Med Clin North Am. 2022 Feb;40(1):99-118. doi: 10.1016/j.emc.2021.09.002. Epub 2021 Oct 29.
3
Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.
Emerg Med Clin North Am. 2022 Feb;40(1):79-98. doi: 10.1016/j.emc.2021.09.004. Epub 2021 Oct 29.
4
An update on factor XII-driven vascular inflammation.
Biochim Biophys Acta Mol Cell Res. 2022 Jan;1869(1):119166. doi: 10.1016/j.bbamcr.2021.119166. Epub 2021 Oct 24.
5
Small molecule drugs for atopic dermatitis, rheumatoid arthritis, and hereditary angioedema.
Ann Allergy Asthma Immunol. 2022 Mar;128(3):263-268. doi: 10.1016/j.anai.2021.10.015. Epub 2021 Oct 18.
6
Diabetic retinopathy, oxidative stress, and sirtuins: an in depth look in enzymatic patterns and new therapeutic horizons.
Surv Ophthalmol. 2022 Jan-Feb;67(1):168-183. doi: 10.1016/j.survophthal.2021.04.003. Epub 2021 Apr 14.
Zotero 插件